New bladder cancer drug aims to fight tumors without harming nerves
NCT ID NCT07662863
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial compares a new targeted drug, sacituzumab tirumotecan (Sac-TMT), to other antibody-drug conjugates (ADCs) in people with advanced urothelial carcinoma (bladder cancer) that has worsened after prior treatment. The main goal is to see if Sac-TMT causes less severe nerve damage while still controlling the cancer. Participants will receive either Sac-TMT or another ADC, and researchers will monitor nerve health through exams, machine tests, and patient surveys.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab tirumotecan (Sac-TMT)
What this could lead to
If successful, this could offer a treatment option for advanced bladder cancer with a lower risk of severe nerve damage, improving quality of life.
What could go wrong
This is a phase II trial with only 75 participants, so results may not apply broadly. The drug may still cause side effects or fail to control the cancer as well as existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact